Shionogi stock closed at ¥3,012 on Friday, roughly flat over the past week, just as fresh Q2 2027 results hit the tape. At first glance the headline looks jarring. Basic earnings per share dropped to ¥25.67 for the quarter, well below the previous three periods, even though revenue reached ¥187,067m.

That mix of firm top line and thinner profit may influence sentiment in the short term. For anyone thinking beyond this quarter, the focus now is on how a business with a 37.9% trailing net margin and a P/E of 10.6x is being priced for the next few years.

Love Shionogi’s high trailing net margin but uneasy about EPS thinning out while revenue holds up? Check out the list of solid balance sheet and fundamentals stocks (21 results).

Q2 2027 Earnings Summary

• Revenue (Q2 2027 vs Q2 2026): ¥187,067m vs. ¥113,184m (up about 65%)
• Net Income (Excl. Extra Items, Q2 2027 vs Q2 2026): ¥21,850m vs. ¥44,187m (down about 51%)
• Basic EPS (Q2 2027 vs Q2 2026): ¥25.67 vs. ¥51.92 (down about 51%)
• Trailing Net Profit Margin (latest vs prior year): 37.9% vs. 39.1% (slight margin compression)

Earnings jumped but forecasts still point to declines. Ask Charlie what makes Shionogi look this cheap.

Shionogi bullish story meets mixed earnings reality

For anyone leaning into Shionogi as a steady healthcare compounder, the latest figures send a split message. Revenue of ¥187,067m, up strongly on Q2 2026, fits the idea of resilient demand and a broad portfolio doing real work. Net income excluding extras and basic EPS both fell by about 51%, which tempers that optimism. Add a still high trailing net margin of 37.9%, only slightly lower than 39.1%, and you get a business that looks commercially solid but currently paying more to keep that top line moving.

Profit squeeze sharpens the Shionogi bear case

Concern about earnings pressure finds more support. Profitability compressed even as sales climbed, with net income excluding special items and EPS both declining by about half year on year. That pattern fits worries around patent pressure, higher R&D spend, or integration costs from moves like the IntraBio deal, even if the exact drivers are not broken out here. Short term share performance backs that muted mood, with the stock roughly flat over 7 days and only modestly ahead over 3 months.

After a quarter where sales climbed but profit compressed sharply, it is fair to ask whether this is a one off or the start of a tougher earnings pattern tied to product cycles, pricing, or pipeline risk. Review the independent risk analysis for Shionogi which shows 1 important warning sign

Hunt For Mispriced Earnings Power

Shionogi shows how a strong business can still report a quarter that leaves investors with hard questions. The real opportunity sits in finding stocks that could be undervalued before the market corrects them.

• Company 1 - 21% below our estimate - supply high precision connectors that device makers adopt as they redesign hardware for faster data and tighter spaces.
• Company 2 - 45% below our estimate - expand fee driven services around core lending as smaller clients seek bundled banking, leasing and capital solutions from a single provider.
• Company 3 - 24% below our estimate - sell data and document platforms firms adopt once manual reporting and invoicing choke off finance and sales teams.

That is three of the list. See the full list of 15 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.